HCPCS Level II
J9351
Injection, topotecan, 0.1 mg
Codes near J9351
These sit next to J9351 in the CMS Level II file. All J codes
- J9345Injection, retifanlimab-dlwr, 1 mg
- J9347Injection, tremelimumab-actl, 1 mg
- J9348Injection, naxitamab-gqgk, 1 mg
- J9349Injection, tafasitamab-cxix, 2 mg
- J9350Injection, mosunetuzumab-axgb, 1 mg
- J9352Injection, trabectedin, 0.1 mg
- J9353Injection, margetuximab-cmkb, 5 mg
- J9354Injection, ado-trastuzumab emtansine, 1 mg
- J9355Injection, trastuzumab, excludes biosimilar, 10 mg
- J9356Injection, trastuzumab, 10 mg and hyaluronidase-oysk
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 00409-0302-01 | Topotecan | Pfizer Inc | 40 |
| 16729-0151-31 | Topotecan | Accord Healthcare Inc | 40 |
| 16729-0243-31 | Topotecan | Accord Healthcare Inc | 40 |
| 45963-0615-56 | Topotecan | Actavis Pharma, Inc. | 40 |
| 63323-0762-10 | Topotecan | FreseniUS Kabi USA, LLC | 40 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.